Antibody Developer Taken Out by Gilead at 'Hefty Premium'
Source: Streetwise Reports  (3/4/20)
The reasons Forty Seven attracted a buyer and its near-term catalysts are provided in a BTIG report. More >

Ocular Therapeutix Shares Climb More than 25% on Q4 Revenue and Phase 1 Wet AMD Clinical Data
Source: Streetwise Reports  (3/4/20)
Ocular Therapeutix shares set a new 52-week high price after the company reported preliminary FY/19 revenue results along with positive interim data from its Phase 1 clinical study of OTX-TKI for treatment of wet age-related macular degeneration. More >

Karyopharm Trades Up 60% on Positive Phase 3 Multiple Myeloma Results
Source: Streetwise Reports  (3/2/20)
Karyopharm Therapeutics shares set a new 52-week high price after the company reported that its Phase 3 BOSTON trial of XPOVIO® achieved significant increases in progression-free survival in patients suffering with multiple myeloma. More >

Sangamo Shares Trade 30% Higher on Q4 Earnings and Biogen Collaboration
Source: Streetwise Reports  (2/28/20)
Sangamo Therapeutics shares traded higher after the company reported Q4/19 and FY/19 earnings and advised that it signed a global collaboration agreement with Biogen to develop gene regulation therapies for Alzheimer's, Parkinson's, neuromuscular and neurological diseases. More >

Moderna Shares Climb on Development of mRNA Vaccine for Phase 1 Coronavirus Study
Source: Streetwise Reports  (2/25/20)
Shares of Moderna traded 23% higher after the company reported that it has developed and shipped an mRNA vaccine against novel coronavirus for use in a Phase 1 testing study in the U.S. More >

Two Stock-Moving Catalysts Expected in March for Biopharma
Source: Streetwise Reports  (2/25/20)
These events for Axsome Therapeutics are described in an H.C. Wainwright & Co. report. More >

NGM Biopharma Shares Rise on Positive Topline Data from Phase 2 NASH Trial
Source: Streetwise Reports  (2/24/20)
Shares of NGM Biopharmaceuticals reached a new 52-week intraday high price after the company posted positive topline data from Cohort 4 of its Phase 2 study of aldafermin in NASH Patients. More >

Baudax Shares Rise as FDA Approves NDA for Its Non-Opioid Pain Medication
Source: Streetwise Reports  (2/21/20)
Shares of Baudax Bio traded more than 20% higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESOâ„¢ drug for management of moderate to severe pain. More >

FDA Approval of Biopharma's Pain Drug Expected This Year
Source: Streetwise Reports  (2/19/20)
The reasons a green light is anticipated and how it relates to the closing of Avenue Therapeutics' pending acquisition are discussed in an H.C. Wainwright & Co. report. More >

Viela Bio Shares Trade Higher After Analyst Issues 'Buy' Recommendation
Source: Streetwise Reports  (2/18/20)
Shares of Viela Bio Inc. rose 20% after an analyst at H.C. Wainwright & Co. initiated coverage of the stock. More >

Life Sciences Firm Contracts with Philippines Distributor
Source: Streetwise Reports  (2/18/20)
This agreement will provide another sales channel and additional revenue opportunities for Avivagen's proprietary product. More >

ImmunoGen Shares Rise 25% on FY/19 Financial Results and Clinical Pipeline Updates
Source: Streetwise Reports  (2/14/20)
Shares of ImmunoGen Inc. reached a new 52-week intraday high price after the company announced FY/19 financial results and reported on recent developments including the completion of a $97.6 million capital raise in January 2020. More >

vTv Therapeutics' Shares Open 80% Higher on Phase 2 Type 1 Diabetes Trial Data
Source: Streetwise Reports  (2/10/20)
Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes. More >

Biopharma Has Three 2020 Shots on Goal in Pediatric Liver Diseases
Source: Streetwise Reports  (2/8/20)
The events in that trio are presented in a ROTH Capital Partners report. More >

Cortexyme Secures $125M Private Placement Capital to Advance Clinical Development
Source: Streetwise Reports  (2/6/20)
Shares of Cortexyme Inc. traded 20% higher after the company reported that it secured an additional $125M in capital from a private placement. The firm intends to use the proceeds to fund current Alzheimer's clinical trials and ongoing operations. More >

Vivus Shares Climb 50% Higher on sNDA Approval for Exocrine Pancreatic Insufficiency Drug
Source: Streetwise Reports  (2/5/20)
Shares of Vivus traded higher after the FDA approved the company's supplemental New Drug Application for an improved formulation of PANCREAZE® (pancrelipase) for use in the treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. More >

Understanding Fortress Biotech
Source: Daniel Carlson for Streetwise Reports  (2/5/20)
Daniel Carlson of Tailwinds Research takes a close look at what he calls a "great value opportunity," with a focus on subsidiary Avenue Therapeutics. More >

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data
Source: Streetwise Reports  (2/3/20)
Insmed Inc.'s shares traded higher today after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis. More >

Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia Trial Results
Source: Streetwise Reports  (1/31/20)
Syndax Pharmaceuticals' shares traded 30% higher after the company reported it expects to raise $35 million from a common stock offering from five institutional investors and secured a $30 million non-dilutive term loan facility. More >

Arcadia Ropes in $3 Million in GoodHemp Seed Purchase Orders Within 50 Days of Product Launch
Source: Streetwise Reports  (1/30/20)
Arcadia Biosciences shares traded 25% higher after reporting that it secured $3 million in pre-season GoodHemp seed purchase commitments in just 50 days after launching the product. More >

Two Approvals Underscore Biotech's Pipeline Quality
Source: Streetwise Reports  (1/29/20)
The green lights and their implications are discussed in an H.C. Wainwright & Co. report. More >

California Gold: Two U.S. Hemp Revenue Streams Coming Online This Quarter
Source: Peter Epstein for Streetwise Reports  (1/29/20)
Peter Epstein of Epstein Research discusses recent developments at the company. More >

Acceleron Shares Open 50% Higher on Phase 2 PAH Trial Data
Source: Streetwise Reports  (1/28/20)
Acceleron Pharma's shares established a new 52-week high after the company reported that sotatercept achieved both primary and secondary endpoints in the Phase 2 PULSAR study in patients with pulmonary arterial hypertension. More >

Inovio Pharma Awarded $9M Development Grant for Coronavirus Vaccine
Source: Streetwise Reports  (1/27/20)
Inovio Pharmaceuticals' shares rose 30%, setting a new 52-week high price, after the firm reported it received a grant of up to $9 million to develop a vaccine against the coronavirus. More >

My Prediction for a Market Top in October Was Perhaps Left but Not Wrong
Source: Bob Moriarty for Streetwise Reports  (1/26/20)
Bob Moriarty of 321gold reflects on how government actions in the financial and public health spheres will pop market bubbles. More >